The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective
ConclusionRivaroxaban 2.5 mg BID plus ASA compared with ASA alone was cost-effective (high value) in the USA.COMPASS ClinicalTrials.gov identifier: NCT01776424.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Aspirin | Cardiology | Cardiovascular | Heart | Heart Attack | Peripheral Vascular Disease (PVD) | Stroke | Study